JAKARTA – Prof. Raymond Tjandrawinata, Professor of Molecular Pharmacology at Atma Jaya University and Molecular Pharmacologist at Dexa Group, has successfully completed his Doctor of Law degree at Universitas Pelita Harapan (UPH), graduating with the distinction of Summa Cum Laude His doctoral research brings together his expertise in pharmaceutical science and law, addressing the need for a healthcare and patent framework that balances the protection of pharmaceutical innov

Dexa Group’s commitment to expanding healthcare access has once again been recognized. The company was honored with The Best Corporate Social Responsibility Award 2026 for Strengthening Social Solidarity and Healthcare Access Through Preventive Actions at the Indonesia Corporate Social and Environmental Responsibility Awards 2026, organized by Warta Ekonomi. The award was presented by Mr. Muhamad Ihsan, Chief Editor of Warta Ekonomi, to Mr. Mateus Ramidi, Manager of Dharma De

Tangerang — Strengthening halal pharmaceutical products has become a shared priority among regulators, industry players, and healthcare providers in Indonesia. Ensuring the halal status of medicines is increasingly seen as essential to delivering safe, high-quality healthcare while providing peace of mind for the public. Indonesia’s Vice Minister of Health, Prof. Dante Saksono Harbuwono, emphasized that expanding halal-certified products is a key part of developing the nation

In less than six months, Indonesia’s pharmaceutical industry landscape is set to change significantly. Starting October 17, 2026, all natural medicines, quasi-drugs, and health supplements distributed across the country must be halal-certified. For Indonesia’s 246 million Muslims—representing 87.08% of the national population, according to the Directorate General of Population and Civil Registration at the Ministry of Home Affairs—this deadline marks a new era: halal assuranc

Halal is not merely an obligation—it is the foundation of trust. From there, quality is reflected and built. As Indonesia approaches the mandatory halal implementation in 2026, Dexa Group is taking concrete steps to ensure every process remains compliant while embodying trusted quality. In line with this commitment, Dexa Group’s Halal Committee has taken decisive action by strengthening collaboration and aligning strategies to prepare for the national halal policy implementat

In the healthcare industry, public trust is not built overnight. It grows through consistent quality assurance, adherence to standards, and contributions that are tangibly felt by society. As demands for transparency continue to rise, healthcare companies are expected not only to deliver good products, but also to establish accurate and responsible communication. For more than five decades, Dexa Group has embraced the philosophy Expertise for the Promotion of Health as the fo

Dexa Medica has once again affirmed its role as a pioneer in Indonesia’s pharmaceutical industry through an award presented by the National Agency of Drug and Food Control (BPOM) of the Republic of Indonesia. The BPOM Achievement Award 2026 in the category of Pioneer with the Highest Number of Phytopharmaceutical Products in Indonesia was presented by the Head of BPOM RI, Prof. Dr. Taruna Ikrar, to the President Director of PT Dexa Medica, Mr. V. Hery Sutanto. The award cerem

Winning the award for eight consecutive times, Dexa Group demonstrates long-term consistency in building public trust. This commitment has once again led Dexa Group to receive the Indonesia Public Relations Awards (IPRA) 2026 with the title of Best Public Relations 2026 in Public Trust Building through Ethical Pharmaceutical Practices. This award affirms Dexa Group’s consistency in safeguarding its corporate reputation through strategic, ethical, and sustainable communication

Dexa Group has once again achieved a strategic milestone by receiving the Indonesia CEO Excellence Award 2025, organized by WartaEkonomi.co.id Research and Consulting. This award recognizes visionary leadership that consistently drives business sustainability while strengthening the pharmaceutical sector’s contribution to national health resilience. The award was presented by Muhamad Ihsan, CEO & Chief Editor of WartaEkonomi.co.id, to Andy Samual, Director of Human Resources

On the occasion of the 61st National Health Day (HKN), Dexa Medica achieved a significant milestone by receiving the Karya Anak Bangsa Award from the Ministry of Health of the Republic of Indonesia, recognizing it as the pharmaceutical industry with the highest number of clinical trials for natural-based drugs in the country. The award was presented during the Health Innovation Festival (HAI-Fest) 2025 held at Kartika Expo Balai Kartini, Jakarta, on Monday, December 8, 2025.